Emodin promotes the recovery of rheumatoid arthritis by regulating the crosstalk between macrophage subsets and synovial fibroblast subsets

Abstract

Background: To study the relationships among emodin, synovial fibroblasts (FLSs), and macrophages (STMs) to provide guidance for the use of emodin in rheumatoid arthritis (RA) treatment.

Methods: RA clinical samples from patients with different pathological processes were collected, and the correlations between the subsets of FLSs and STMs and pathological processes were analyzed via flow cytometry. In vitro experimental methods such as enzyme linked immunosorbent assay (ELISA), Western blotting, Transwell assays, CCK-8 assays and cell coculture were used to assess cell proliferation, migration and secretion of inflammatory factors. A collagen-induced arthritis mouse model was constructed to investigate the therapeutic potential of emodin in RA by flow cytometry, micro-CT and staining.

Results: Unique subsets of FLSs and STMs, namely, FAPα⁺THY1^- FLSs, FAPα⁺THY1⁺ FLSs, and MerTK^posTREM2^high STMs, were identified in synovial tissues from RA patients. The number of MerTK^posTREM2^high STMs was negatively correlated with the degree of damage in RA, while the number of FAPα⁺THY1^- FLSs was positively correlated with damage. On the one hand, emodin promoted the aggregation of MerTKposTREM2high STMs. Moreover, MerTK^posTREM2^high STM-mediated secretion of exosomes was promoted, which can inhibit the secretion of pro-inflammatory factors by FAPα⁺THY1⁺ FLSs and promote the secretion of anti-inflammatory factors by FAPα⁺THY1⁺ FLSs, thereby inhibiting FAPα⁺THY1^-FLS proliferation and migration, improving the local immune microenvironment, and inhibiting RA damage.

Conclusion: Emodin was shown to regulate the aggregation of STM subsets and exosome secretion, affecting the secretion, proliferation and migration of inflammatory factors in FLS subsets, and ultimately achieving good therapeutic efficacy in RA patients, suggesting that it has important clinical value.

Keywords

emodin / fibroblast synoviocytes / macrophages / rheumatoid arthritis

References

[1] SmolenJS, Aletaha D, McInnesIB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038.

[2] McInnesIB, SchettG. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.

[3] LeeDM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903-911.

[4] ShiN, ZhangS, SilvermanG, Li M, CaiJ, NiuH. Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis. Animal Model Exp Med. 2019;2(2):98-106.

[5] ZhangY, MaoX, LiW, et al. Tripterygium wilfordii: an inspiring resource for rheumatoid arthritis treatment. Med Res Rev. 2021;41(3):1337-1374.

[6] MeiHX, TaoY, ZhangTH, Qi F. Emodin alleviates LPS-induced inflammatory response in lung injury rat by affecting the function of granulocytes. Acta Pharmacol Sin. 2020;17(1):26.

[7] ZhuM. Emodin ameliorates rheumatoid arthritis by promoting neutrophil apoptosisand inhibiting neutrophil extracellular trap formation. Mol Immunol. 2019;112:188-197.

[8] GuptaSC. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch Biochem Biophys. 2014;559:91-99.

[9] HendersonNC, RiederF, WynnTA. Fibrosis: from mechanisms to medicines. Nature. 2020;587(7835):555-566.

[10] CroftAP, CamposJ, JansenK, et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature. 2019;570(7760):246-251.

[11] AliverniniS, MacDonald L, ElmesmariA, et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat Med. 2020 Aug; 26(8):1295-1306.

[12] ShimodaK, SauveY, MariniA, Schwartz JP, CommissiongJW. A high percentage yield of tyrosine hydroxylase-positive cells from ratE14 mesencephalic cell culture. Brain Res. 1992;586(2):319-331.

[13] HwangJK, NohEM, MoonSJ, et al. Emodin suppresses inflammatory responses and joint destruction in collagen-induced arthritic mice. Rheumatology. 2013;52:1583-1591.

[14] WeiK, Korsunsky I, MarshallJL, et al. Notch signaling drives synovial fibroblast identity and arthritis pathology. Nature. 2020;582(7811):259-264.

[15] AliverniniS, PelusoG, FedeleAL, Tolusso B, GremeseE, FerraccioliG. Tapering and discontinuation of TNF-alpha blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis ResTher. 2016;18:39.

[16] AliverniniS, Tolusso B, PetriccaL, et al. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission? Ann Rheum Dis. 2017;76:1228-1336.

[17] QianH, ZhangS, YangY, et al. Extracellular vesicles in the pathogenesis and treatment of acute lung injury. Mil Med Res. 2022;9(1):61.

[18] LiangZ, RenC. Retraction notice to “Emodin attenuates apoptosis and inflammation induced by LPS through up-regulating lncRNA TUG1 in murine chondrogenic ATDC5 cells”. Biomed Pharmacother. 2018;103:897-902.

[19] ChengL, ChenJ, RongX. Mechanism of emodin in the treatment of rheumatoid arthritis. J Evid Based Complementary Altern Med. 2022;2022:9482570.

[20] QuK, ShenNY, XuXS, SuHB. Emodin induces human T cell apoptosis in vitro by ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction. Acta Pharmacol Sin. 2013;34:1-12.

RIGHTS & PERMISSIONS

2024 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.